Canine Atopic Dermatitis Market Forecast 2026–2035 Driven by Key Industry Factors

April 8, 2026April 8, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Allergy Conjunctivitis Market Expected To Change Between 2026 And 2030?

The market for canine atopic dermatitis has seen rapid expansion in recent years. It will grow from $2.76 billion in 2025 to $3.05 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth observed in the past can be attributed to an increasing prevalence of allergic skin conditions in dogs, heightened awareness among pet owners and veterinarians, a previous scarcity of targeted treatments, the adoption of glucocorticoids and antihistamines as primary therapies, and the expansion of veterinary dermatology services.

The market for canine atopic dermatitis is projected to experience substantial expansion in the coming years. This market is forecast to reach $4.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.2%. Factors contributing to this growth during the forecast period include the advancement of new biologics and monoclonal antibodies (mAbs), greater investment in precision medicine for companion animals, increased use of topical and systemic immunotherapies, the expansion of online and retail distribution channels, and an emphasis on preventive and supportive care, such as nutraceuticals. Key trends expected within this period involve the rising application of monoclonal antibodies (mAbs) for targeted therapies, the expanding uptake of allergen-specific immunotherapy (ASIT) in canines, a greater need for medicated shampoos and topical solutions, the broadening use of nutraceuticals and probiotics to support skin barrier health, and a concentration on treatment strategies tailored to specific dog breeds for canine atopic dermatitis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25717&type=smp

Which Economic Or Industry Drivers Are Impacting The Allergy Conjunctivitis Market?

A projected increase in instances of canine skin allergies is anticipated to drive the expansion of the canine atopic dermatitis market. These allergies represent unusual immune reactions in dogs to various allergens, including pollen, specific foods, or flea bites, leading to symptoms such as itching, skin redness, and irritation. The escalation in canine skin allergy occurrences is partly linked to greater exposure to environmental contaminants and allergens, which can provoke intensified immune reactions and irritate the skin. Treatments for canine atopic dermatitis assist in controlling these skin allergies by mitigating inflammation and itchiness, and by averting subsequent infections, ultimately enhancing the dogs’ comfort and dermatological well-being. For example, data from January 2024 by the National Institutes of Health (NIH), a US government agency, indicated that 7,915 dog owners, representing 28.7%, reported their dogs previously experienced skin conditions. The frequency of these reported skin problems showed a consistent increase with age, from 7% in puppies to 37% in older dogs. Consequently, the growing number of canine skin allergy cases is fostering the expansion of the canine atopic dermatitis market. The increasing trend of pet ownership is projected to stimulate the growth of the canine atopic dermatitis market in the future. Pet ownership involves maintaining and looking after a domesticated creature, like a dog, cat, or bird, as a household companion. This rise is attributed to the growing humanization of pets, where animals are regarded as family members, thereby boosting the demand for their companionship and the emotional support they provide. Addressing canine atopic dermatitis offers advantages for pets by alleviating persistent itching and inflammation, fostering better skin health, and improving their general comfort and standard of living. For example, the American Pet Products Association (APPA), a US trade group for pet product manufacturers and suppliers, reported in April 2025 that 94 million US households, or 71%, will own a pet in 2025, an increase from 86.9 million households (66%) in 2023-2024. Thus, the expanding rate of pet ownership is propelling the growth within the canine atopic dermatitis market.

How Is The Allergy Conjunctivitis Market Structured Across Different Segments?

The canine atopic dermatitis market covered in this report is segmented –

1) By Product: Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibodies (mAbs), Other Products

2) By Dog Breed: German Shepherd, Terriers, Retrievers, Other Dog Breeds

3) By Indication: Ectoparasites, Food Allergy, Allergic Skin Infections, Other Indications

4) By Route Of Administration: Oral, Topical, Injectable

5) By Distribution Channel: Veterinary Clinics, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

2) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

3) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

4) By Monoclonal Antibodies: Lokivetmab, Investigational Monoclonal Antibodies

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

Which Trends Are Shaping The Future Of The Canine Atopic Dermatitis Market?

Companies operating in the canine atopic dermatitis market are primarily focused on securing regulatory approvals to expand the accessibility and adoption of their treatments across international markets. Regulatory approvals are the official permissions granted by government health authorities, allowing companies to sell their medical products after demonstrating their safety, effectiveness, and quality through rigorous testing. For example, in September 2024, Elanco Animal Health Inc., an animal health pharmaceutical company based in the US, obtained US FDA approval for Zenrelia, an oral JAK inhibitor administered once daily for dogs with allergic and atopic dermatitis. Zenrelia’s approval represents a significant step forward in managing dogs afflicted with chronic, acute, or seasonal itch and inflammation, offering a comprehensive solution in a single, daily tablet from the start. It functions by targeting the core source of the itch, blocking the specific pathways responsible for allergic itch to disrupt the itch-scratch cycle. Zenrelia delivers clear improvement from the first dose and reduces the likelihood of rebound itch, a frequent problem in many dogs treated with competing JAK inhibitors.

Which Major Players Dominate The Allergy Conjunctivitis Market?

Major companies operating in the canine atopic dermatitis market are Merck & Co. Inc., Zoetis Inc., Hill’s Pet Nutrition Inc., Royal Canin SAS, Ceva Santé Animale S.A., Virbac S.A., Elanco Animal Health Inc., Dechra Pharmaceuticals PLC, Vetoquinol S.A., Bioiberica S.A.U., Bimeda Animal Health Limited, Animal Dermatology Group Inc., Kindred Biosciences Inc., Nextmune AB, OKAVA Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Toray Industries Inc., LEO Pharma A/S, PetIQ Inc., Hester Biosciences Limited, Ourofino Saude Animal, Swedencare AB, Orion Corporation, Norbrook Laboratories Ltd., AB Science SA.

Read the full canine atopic dermatitis market report here:

https://www.thebusinessresearchcompany.com/report/canine-atopic-dermatitis-global-market-report

What Are The Top-Performing Regions Within The Allergy Conjunctivitis Market?

North America was the largest region in the canine atopic dermatitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the canine atopic dermatitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Allergy Conjunctivitis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25717&type=smp

Browse Through More Reports Similar to the Global Canine Atopic Dermatitis Market 2026, By The Business Research Company

Dermatitis Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Veterinary Dermatology Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-dermatology-drugs-global-market-report

Dog Vaccines Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795